Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase

This folder will just contained published patents after I post them on home page so no need to comment here.
Post Reply
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase

Post by TimGDixon »

This patent is published but not publicly viewable at this time. In fact this patent has been granted and we are just waiting for official announcement in the USPTO Gazette after receiving Notice of Allowance last week.


Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase
Disclosed are compositions of matter, treatments and protocols useful for reduction of expression and/or activity of indolamine 2,3 deoxygenase (IDO). In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at possessing an increased expression and/or activity of said IDO in which reduction of number and/or activity is desired. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with viral and/or bacterial infections and/or neoplasia. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients.


Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies

Continued Basic Science Experiments Support New Patent Filing Covering Suppression of Indolamine 2,3 Deoxygenase Pathway by QuadraMune™
June 15, 2020 09:00 ET | Source: Therapeutic Solutions International, Inc.


OCEANSIDE, CA — June 15, 2020 — InvestorsHub NewsWire — Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the filing of a new patent covering suppression of the indolamine 2,3 deoxygenase (IDO) pathway by QuadraMune™ administration.

In the study, mice were administered lipopolysaccharide (LPS), a compound known to stimulate inflammation, in order to replicate inflammation-associated depression. Mice receiving LPS suffered a reduction in memory activity, as quantified using the Morris Water Maze test.

Administration of QuadraMune™ significantly inhibited inflammation associated with memory impairment, as well as reduced levels of kynurenine. Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation and depression [1].

“The current data support the possibility of QuadraMune™ being used as an adjuvant to numerous immune therapies whose efficacy is currently inhibited by the depression-inducing and immune blocking effects of the indolamine 2,3 deoxygenase enzyme,” said Dr. James Veltmeyer, Chief Medical Officer and co-inventor of the current patent. “Many times, when you activate the immune system, cells in the body,and in the brain, start producing the enzyme indolamine 2,3 deoxygenase, whose role is to restrain the immune system, and for reasons unknown, causes depression. By manipulating this enzyme through natural means, we are optimistic that we can enhance the efficacy of numerous immune modulatory treatments for viral and neoplastic conditions.”

Dr. Thomas Ichim, Board Member of Therapeutic Solutions International, has been working on this enzyme since 2013 when he published in the peer-reviewed literature regression of breast cancer using RNA interference to block its expression [2].

“From a commercialization perspective we are truly optimistic about the implications of the current results, which may require us to consider expanding our clinical trial programs,” said Timothy Dixon, President, and CEO of the Company. “The IDO enzymatic pathway is not only extremely interesting from a medical perspective, but companies working on manipulating this pathway have previously entered Big Pharma deals with potential values in excess of $1 billion [3]. In contrast to other programs that utilize synthetic approaches, QuadraMune™, which is comprised of natural ingredients and is available as a nutraceutical, may possess numerous advantages for accelerated commercialization.”

[1] Lanser et al. Inflammation-Induced Tryptophan Breakdown Is Related With Anemia, Fatigue, and Depression in Cancer. Front Immunol . 2020 Feb 21;11:249. https://www.frontiersin.org/articles/10 ... 00249/full

[2] Zheng et al. Silencing IDO in Dendritic Cells: A Novel Approach to Enhance Cancer Immunotherapy in a Murine Breast Cancer Model. Int J Cancer. 2013 Feb 15;132(4):967-77 https://pubmed.ncbi.nlm.nih.gov/22870862/

[3] https://news.bms.com/press-release/rd-n ... cquire-fle
TSOI_Ry
Posts: 75
Joined: Mon Jun 29, 2020 12:19 pm
Location: Seattle, Wa

Re: Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase

Post by TSOI_Ry »

Thank you for the clarification, Tim! I miss spoke when I assumed it had been published. I can see now that it hasn’t been officially published. Looking forward to when it is!

Very exciting stuff! 😎
TradersTrader🍻
“Through adversity, comes strength...”
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Re: Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase

Post by TimGDixon »

When the USPTO sent the Notice of Allowance they also requested that we submit our declarations which we did and thats the likely reason it didn't publish.
TSOI_Ry wrote: Sun Dec 19, 2021 4:51 pm Thank you for the clarification, Tim! I miss spoke when I assumed it had been published. I can see now that it hasn’t been officially published. Looking forward to when it is!

Very exciting stuff! 😎
TSOI_Ry
Posts: 75
Joined: Mon Jun 29, 2020 12:19 pm
Location: Seattle, Wa

Re: Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase

Post by TSOI_Ry »

Makes sense 👍🏼 Congratulations, sorry I jumped the gun! Very exciting milestone.
TradersTrader🍻
“Through adversity, comes strength...”
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Re: Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase

Post by TimGDixon »

Its all good. Very few nutraceuticals are patented if you survey whats out there and in this case the examiner found no prior artwork; so, this first QM patented granted will be the prior artwork and the other 11 will all point back to this one. Good times ahead.
TSOI_Ry wrote: Sun Dec 19, 2021 6:39 pm Makes sense 👍🏼 Congratulations, sorry I jumped the gun! Very exciting milestone.
Post Reply